Sweden: Saga Diagnostics raises SKr40m Series A funding

Lao Saal, founder and chief executive, Saga Diagnostics

Lund-based Saga Diagnostics, a precision oncology genomics testing company focused on ultrasensitive monitoring of cancer patients using blood samples and other liquid biopsies and tissue has raised SKr40m (US$4.2m) in venture-backed financing. The round was led by Nordic-focused European life science fund manager Hadean Ventures, joined by a number of existing shareholders including Fårö Capital…

You must be a HMI Subscriber to view this content. Please log in or subscribe below.

Subscribe Now »